What is the difference between Cyltezo and Humira?
Medically reviewed by Drugs.com Last updated on Sep 16, 2019.
Official Answer
by Drugs.comCyltezo (adalimumab-adbm) is a biosimilar to Humira (adalimumab).
Cyltezo is not an interchangeable product with Humira; the physician must write a prescription specifically for Cyltezo.
A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Humira), and has no clinically meaningful differences in terms of safety and effectiveness.
What Are Biosimilars? Top Facts You May Not Know
Both Cyltezo and Humira belong to the class of drugs called anti-TNF-α monoclonal antibodies.
Both biologics are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis.
For more information see Comparing Cyltezo vs Humira
Related Medical Questions
- What is the difference between Amjevita and Humira?
- How many biosimilars have been approved in the United States?
- What are the new drugs for the treatment of plaque psoriasis?
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- Can you take Humira with antibiotics?
- How much does Humira cost without insurance?
- How long can Humira be out of the fridge?
Drug Information
Related Support Groups
- Humira (88 questions, 335 members)
- Adalimumab
- Cyltezo
- Rheumatoid Arthritis (373 questions, 1198 members)
- Crohn's Disease (38 questions, 264 members)
- Psoriatic Arthritis (41 questions, 234 members)
- Ulcerative Colitis (30 questions, 168 members)
- Plaque Psoriasis (18 questions, 62 members)
- Juvenile Idiopathic Arthritis
